stated Yufeng Jane Tseng, PhD, Chief Executive Officer of YODA. MSA is a rare, rapidly progressive, and fatal neurodegenerative disorder characterized by motor impairment (parkinsonism or ...

Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 trial of YA-101 for Multiple ...